Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2 × ruxolitinib × Tumor-Agnostic × Clear all

Phase

Phase 2 1 Phase 1 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Myeloid 25 Other hematologic neoplasm 20 Lymphoid 14 Breast 5 Thoracic 2 Dermatologic 2 Classical hematology 2 Tumor-Agnostic 1 Plasma cell 1 Other solid neoplasm 1 Head & Neck 1 Genitourinary 1 CNS 1

Conditions

Neoplasm Metastasis 1

Interventions

Paclitaxel 23 Gemcitabine 22 pembrolizumab 21 Carboplatin 21 Radiotherapy 14 Oxaliplatin 14 Cisplatin 14 Bevacizumab 14 Nivolumab 13 Erlotinib Hydrochloride 13 Fluorouracil 12 Capecitabine 12 Trastuzumab 11 Magnetic Resonance Spectroscopy 10 Leucovorin 10 Docetaxel 10 atezolizumab 9 Irinotecan 9 Everolimus 9 Vemurafenib 8 Ipilimumab 8 Cyclophosphamide 8 130-nm albumin-bound paclitaxel 8 Specimen Handling 7 Radiosurgery 7 Albumin-Bound Paclitaxel 7 Afatinib 7 lenvatinib 6 durvalumab 6 cabozantinib 6

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT02142036 2019-03-13

MetAction

Oslo University Hospital

Phase 2 Completed

Neoplasm Metastasis

Data powered by HemOnc (CC BY 4.0) Colophon ⚡